Mild and moderate stress urinary incontinence
After IncontiLase® treatment
IncontiLase® is an innovative, patented, Er:YAG laser therapy for mild and moderate stress urinary incontinence (SUI) based on the revolutionary, non-invasive Fotona SMOOTH® technology.
The 2940 nm Er:YAG laser used for IncontiLase® features abuilt-in proprietary technology called Fotona SMOOTH® that enables delivery of precisely controlled laser-induced thermal effects that stimulate collagen neogenesis and remodeling in the mucosa tissue (in the region of the vestibule and urethra lorifice, as well as in the area along the anterior vaginal wall).
The end result of the IncontiLase® treatment is non-ablative photothermal tension, shrinkage and tightening of the tissue in the urethral and anterior bladder wall region and the return of normal continence function.
For the majority of patients, two sessions of IncontiLase® with a one-month interval were sufficient to alleviate mild or even moderate stress urinary incontinence. No special pre-op preparations or post-op precautions were necessary. Patients could immediately return to their normal everyday activities. Additional advantages of IncontiLase® are that the procedure is incisionless and virtually painless, with no ablation, cutting, bleeding, or sutures. Recovery is extremely quick without need for the use of analgesics or antibiotics.
The effect of IncontiLase® therapy on the improvement of the grade of urinary incontinence (UI). The figure shows the distribution of patients(in %) with regard to the grade of incontinence (mild, moderate, severe, very severe) before treatment, at 3 months, 6 months and 1 year after the procedure
Novel minimally invasive laser treatment of urinary incontinence in women. Ogrinc UB, Senčar S, Lenasi H. Lasers Surg Med., 2015: 47(9): 689-697.
Since the introduction of Fotona SMOOTH® minimally invasive laser gynecology in 2012, more than 35 SCI (high Science Citation Index) publications have been published in the most highly respected, peer-reviewed international journals. These studies all show excellent results in the improvement of incontinence and other genitourinary symptoms.
IncontiLase® treatment significantly reduced leakage quantity as measured by 1h pad test.
Tien, Yi-Wen, et al. “Effects of laser procedure for female urodyn amicstress incontinence on pad weight, urodynamics, and sexual function.” International urogyn ecology journal 28.3 (2017): 469-476.
Visit the Fotona (www.fotona.com) or Laser and Health Academy (www.laserandhealth.com) websites to learn more about IncontiLase® and other Fotona SMOOTH® treatments, as well as training opportunities under the guidance of experts in medical laser technology.
"I would certainly recommend the Fotonalaser to colleagues. I see the future ofgynecology having greater emphasis basedon out-patient treatments rather thaninvasive surgical treatments, whereverpossible and appropriate."
One year following the IncontiLase®treatment, we found significant improvementin 77% of patients diagnosed with SUI.
Apart from non-invasiveness, the mainadvantage of IncontiLase® over surgeryis that it can be applied as an ambulatoryprocedure, which means a lower economicburden.
All Fotona medical lasers are CE marked and approved to be sold in the EU. For countries where specific national approvals or clearances are required, some of the products and/or applications may not yet have been approved. Please check with Fotona, your local Fotona distributor or your national regulatory body about whether a specific product or application has been approved to be marketed and sold in your country.
IntimaLase® is an innovative and unique, patented, noninvasive Er:YAG laser therapy for treatment of vaginal relaxation syndrome, a condition which is generally associated with overstretching of the vaginal canal during childbirth as well as with natural ageing.
The IntimaLase® treatment is based on a proprietary 2940nm Er:YAG laser technology called Fotona SMOOTH®, which enables delivery of specially composed laser energy pulses to the vaginal mucosa tissue.
The precisely controlled Fotona SMOOTH® energy pulses are designed to induce thermal effects in the vaginal tissue, stimulating collagen remodeling and the synthesis of new collagen fibers. The end result of collagen neogenesis and re modeling is tightening of the vaginal canal.
For the majority of patients, two sessions with a one-month interval are sufficient for significant tightening of the vaginal canal. No special pre-op preparation or post-op precautions are necessary. Patients can immediately return to their normal every day activities.
Gaviria J, Lanz J. Laser Vaginal Tightening (LVT) – evaluation of a novelnoninvasive laser treatment for vaginal relaxation syndrome. LA&HAJournal of Laser and Health Academy, 2012(1); 46-58.
Since the introduction of Fotona SMOOTH® minimally invasive laser gynecology in 2012, more than 35 SCI (high Science Citation Index) publications have been published in the most highly respected, peer-reviewed international journals. These studies all show excellent results in the improvement of vaginal laxity and other genitourinary symptoms.
IntimaLase® treatment
Visit the Fotona (www.fotona.com) or Laser and Health Academy (www.laserandhealth.com) websites to learn more about IntimaLase® and other Fotona SMOOTH® treatments, as well as training opportunities under the guidance of experts in medical laser technology.
"IntimaLase® has opened another window inmy brain for helping my patients who werebothered by sexual dissatisfaction due tovaginal relaxation syndrome. Throughoutthe period of time I have used vaginal laserrejuvenation therapy, I have witnessed manypatients repair the relationships with theirpartners after receiving the IntimaLase®procedure."
"95% of my patients assess vaginal tightness and sexual gratificatication as strongly ormoderately improved after IntimaLase® treatment."
All Fotona medical lasers are CE marked and approved to be sold in the EU. For countries where specific national approvals or clearances are required, some of the products and/or applications may not yet have been approved. Please check with Fotona, your local Fotona distributor or your national regulatory body about whether a specific product or application has been approved to be marketed and sold in your country.